Abeona Therapeutics Announces European Regulatory Approval for Phase 1/2 Gene Therapy Clinical Study for Patients With Sanfilippo Syndrome Type A (MPS IIIA) Aug 4, 2016
Abeona Therapeutics Provides Update on Initial Subjects in Sanfilippo Type A Gene Therapy Trial, Demonstrating Encouraging Early Biopotency Signals Aug 2, 2016
Abeona Therapeutics Announces FDA Allowance of Investigational New Drug (IND) for Phase 1/2 Clinical Study With ABO-101 Gene Therapy for Patients With Sanfilippo Syndrome Type B (MPS IIIB) May 24, 2016
Abeona Therapeutics Doses First Patient in Phase 1/2 Trial With ABO-102 Gene Therapy for Patients With Sanfilippo Syndrome Type A (MPS IIIA) May 17, 2016
Abeona Therapeutics Announces First Quarter 2016 Summary Financial Results and Recent Operational Highlights May 16, 2016
Abeona Therapeutics Appoints Christine Silverstein as Vice President of Investor Relations May 3, 2016
